Key facts
- Orexa’s last known valuation is $14.3M (Jan 2025).
- It has raised $4.6M; the latest was Later Stage VC ($650K) in Jan 2025.
- Notable investors include Stichting Participatie Atriva, Vectrix (Netherlands).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Orexa
- ·The full record, as it builds
Funding rounds
No funding rounds for Orexa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orexa
Developer of commercial therapeutics designed to help increase food intake and improve health. The company's formulation leads to the local analgesic action in the stomach and a delay in the signaling to the brain that the stomach is full offering a slower onset of satiety, leading to an increased food intake, enabling healthcare professionals to prevent of post-operative ileus.
- Sector
- Healthcare
- HQ
- Herpen, Netherlands
- Founded
- 2016
- Employees
- 4
- Website
- orexa.eu/
- Ownership
- Privately Held (backing)
Orexa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orexa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orexa in its N-PORT filings yet. We sweep new filings monthly.